

Official Journal

of the European Communities

ISSN 0378-6986

C 157

Volume 45

2 July 2002

English edition

Information and Notices

<u>Notice No</u>	<u>Contents</u>	<u>Page</u>
	I <i>Information</i>	
	Commission	
2002/C 157/01	Euro exchange rates	1
2002/C 157/02	Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 May to 15 June 2002 (<i>Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93</i>)	2
2002/C 157/03	Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 May to 15 June 2002 (<i>Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council</i>)	6
2002/C 157/04	Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty — Cases where the Commission raises no objections	25
2002/C 157/05	Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty — Cases where the Commission raises no objections	26
2002/C 157/06	Prior notification of a concentration (Case COMP/M.2890 — EDF/Seaboard) ⁽¹⁾	28
2002/C 157/07	Notice under Section 12(2) of the Telecommunications Act 1984 — Proposed modifications to the licence of British Telecommunications plc (BT) ⁽¹⁾	28



I

(Information)

COMMISSION

Euro exchange rates ⁽¹⁾

1 July 2002

(2002/C 157/01)

1 euro =

Currency	Exchange rate	Currency	Exchange rate		
USD	US dollar	0,9913	LVL	Latvian lats	0,5969
JPY	Japanese yen	118,72	MTL	Maltese lira	0,4171
DKK	Danish krone	7,4278	PLN	Polish zloty	4,0072
GBP	Pound sterling	0,6469	ROL	Romanian leu	33041
SEK	Swedish krona	9,079	SIT	Slovenian tolar	226,1959
CHF	Swiss franc	1,4699	SKK	Slovak koruna	43,909
ISK	Iceland króna	85,89	TRL	Turkish lira	1567000
NOK	Norwegian krone	7,414	AUD	Australian dollar	1,7667
BGN	Bulgarian lev	1,951	CAD	Canadian dollar	1,504
CYP	Cyprus pound	0,57954	HKD	Hong Kong dollar	7,732
CZK	Czech koruna	29,253	NZD	New Zealand dollar	2,04
EEK	Estonian kroon	15,6466	SGD	Singapore dollar	1,7509
HUF	Hungarian forint	244,13	KRW	South Korean won	1190,55
LTL	Lithuanian litas	3,4526	ZAR	South African rand	9,8094

⁽¹⁾ Source: reference exchange rate published by the ECB.

**Summary of Community decisions on marketing authorisations in respect of medicinal products
from 15 May to 15 June 2002**

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 ⁽¹⁾)

(2002/C 157/02)

— Issuing of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
17.5.2002	Memantine Merz Pharmaceuticals GmbH	Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100-104 D-60318 Frankfurt am Main	EU/1/02/218/001-006	22.5.2002
17.5.2002	Opatanol	Alcon Laboratories (UK) Ltd Pentagon Park Boundary Way Hemel Hempstead Herts HP2 7UK United Kingdom	EU/1/02/217/001-002	22.5.2002

— Modification of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
17.5.2002	Rebif	Serono Europe Ltd 56 Marsh Wall London E14 9TP United Kingdom	EU/1/98/063/001-006	22.5.2002
17.5.2002	Agenerase	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/00/148/001-004	22.5.2002
17.5.2002	Remicade	Centocor BV Einsteinweg 101 2333 CB Leiden Nederland	EU/1/99/116/001-003	22.5.2002
17.5.2002	Aerius	Schering Plough Europe Rue de Stalle/Stallestraat 73 B-1180 Bruxelles/Brussel	EU/1/00/160/001-013	22.5.2002
17.5.2002	Allex	Schering Plough Europe Rue de Stalle/Stallestraat 73 B-1180 Bruxelles/Brussel	EU/1/00/159/001-013	22.5.2002
17.5.2002	Azomyr	Schering Plough Europe Rue de Stalle/Stallestraat 73 B-1180 Bruxelles/Brussel	EU/1/00/157/001-013	22.5.2002

⁽¹⁾ OJ L 214, 24.8.1993, p. 1.

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
17.5.2002	Neoclarityn	Schering Plough Europe Rue de Stalle/Stallestraat 73 B-1180 Bruxelles/Brussel	EU/1/00/161/001-013	22.5.2002
17.5.2002	Opulis	Schering Plough Europe Rue de Stalle/Stallestraat 73 B-1180 Bruxelles/Brussel	EU/1/00/158/001-013	22.5.2002
17.5.2002	Trisenox	Cell Therapeutics (UK) Limited 100 Pall Mall London SW 1Y 5HP United Kingdom	EU/1/02/204/001	22.5.2002
22.5.2002	Herceptin	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/00/145/001	27.5.2002
24.5.2002	Visudyne	Novartis Ophthalmics Europe Ltd Delta House Southwood Crescent Southwood Farnborough Hants GU 14 0NL United Kingdom	EU/1/00/140/001	28.5.2002
24.5.2002	Synagis	Abbott Laboratories Ltd Queenborough Kent ME11 5EL United Kingdom	EU/1/99/117/001-002	28.5.2002
24.5.2002	Zenapax	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/99/098/001-002	28.5.2002
24.5.2002	Glivec	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/01/198/001-006	29.5.2002
30.5.2002	Micardis	Boehringer Ingelheim International GmbH Binger Straße 173 D-55216 Ingelheim am Rhein	EU/1/98/090/001-014	3.6.2002
30.5.2002	Telmisartan	Boehringer Ingelheim International GmbH Binger Straße 173 D-55216 Ingelheim am Rhein	EU/1/98/091/001-014	3.6.2002
30.5.2002	Pritor	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/98/089/001-016	5.6.2002

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
30.5.2002	Emadine	Alcon Laboratories (UK) Ltd Boundary Way Hemel Hempstead Herts HP2 7UK United Kingdom	EU/1/98/095/003-004	5.6.2002
4.6.2002	Zyprexa	Eli Lilly Nederland BV Grootslag 1-5 3991 RA Houten Nederland	EU/1/96/022/001-015	6.6.2002
4.6.2002	Zyprexa Velotab	Eli Lilly Nederland BV Grootslag 1-5 3991 RA Houten Nederland	EU/1/99/125/001-004	6.6.2002
4.6.2002	Olansek	Eli Lilly UK Ltd Kingsclere Road Basingstoke Hampshire United Kingdom	EU/1/96/021/001-010	6.6.2002
7.6.2002	Gonal-F	Serono Europe Limited 56 Marsh Wall London E14 9TP United Kingdom	EU/1/95/001/001-030	13.6.2002
7.6.2002	Gonal-F	Serono Europe Limited 56 Marsh Wall London E14 9TP United Kingdom	EU/1/95/001/022-030	13.6.2002
7.6.2002	Gonal-F	Serono Europe Limited 56 Marsh Wall London E14 9TP United Kingdom	EU/1/95/001/031	12.6.2002
7.6.2002	Ketek	Aventis Pharma SA 20, avenue Raymond-Aron F-92160 Antony	EU/1/01/191/001-004	12.6.2002
7.6.2002	Levviac	Aventis Pharma SA 20, avenue Raymond-Aron F-92160 Antony	EU/1/01/192/001-004	12.6.2002
11.6.2002	Viracept	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/97/054/001-005	13.6.2002
12.6.2002	Aprovel	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/97/046/001-015	14.6.2002
12.6.2002	Karvea	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/97/049/001-015	14.6.2002

— **Withdrawal of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93)**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
24.5.2002	NovoRapid	Novo Nordisk A/S Novo Allé DK-2880 Bagsværd	EU/1/99/119/002, EU/1/99/119/004	28.5.2002
11.6.2002	Orlaam	Sipaco Internacional Lda Avenida 5 de Outubro 267 — 6.º dto P-1600 Lisboa	EU/1/97/041/001-002	18.6.2002
11.6.2002	Zartra	3M Santé Boulevard de l'Oise F-95029 Cergy Pontoise Cedex	EU/1/98/079/001	13.6.2002

— **Modification of a marketing authorisation (Article 34 of Regulation (EEC) No 2309/93): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
17.5.2002	Suvaxyn Aujeszky 783 +O/W	Fort Dodge Animal Health Holland C.J. van Houtenlaan 36 1381 CP Weesp Nederland	EU/2/98/009/001-006	22.5.2002
22.5.2002	Eurican Herpes 205	Merial 17, rue Bourgelat F-69002 Lyon	EU/2/01/029/001-002	24.5.2002
22.5.2002	Porcilis Porcoli	Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer Nederland	EU/2/96/001/003-008	24.5.2002

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal Products
7 Westferry Circus
Canary Wharf
London E14 4HB
United Kingdom.

**Summary of Community decisions on marketing authorisations in respect of medicinal products
from 15 May to 15 June 2002**

*(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council ⁽¹⁾
or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council ⁽²⁾)*

(2002/C 157/03)

— Issuing, maintenance or modification of a national marketing authorisation

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorisation	Member State concerned	Date of notification
30.5.2002	Fluvoxamine	See Annex I	See Annex I	3.6.2002
30.5.2002	Cisapride	See Annex II	See Annex II	3.6.2002

⁽¹⁾ OJ L 311, 28.11.2001, p. 67.

⁽²⁾ OJ L 311, 28.11.2001, p. 1.

ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES

Member State	Marketing authorisation holder	Invented names	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
AUSTRIA	Solvay Pharma GesmbH. Donaustraße 106 A-3400 Klosterneuburg	Floxyfral	50 mg 100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC blisters	50 mg — 5, 30 and 60 100 mg — 15 and 30
BELGIUM	Solvay Pharma & Cie., SNC-VOF Bd. Em. Bockstaellaan 122 B-1020 Brussels	Floxyfral	100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC blisters	20, 30 and 60 Hospital pack of 100 (UD)
	Solvay Pharma & Cie., SNC-VOF Bd. Em. Bockstaellaan 122 B-1020 Brussels	Dumirox	100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC blisters	30 and 60 Hospital pack of 100 (UD)
	Solvay Pharma & Cie., SNC-VOF Bd. Em. Bockstaellaan 122 B-1020 Brussels	Maleate de Fluvoxamine	100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC blisters	30 and 60 Hospital pack of 100 (UD)
DENMARK	Solvay Pharmaceuticals BV C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands	Fevarin	50 mg 100 mg	Tablets	Oral use	PVC/PVDC-A1 blisters	30, 60 and 90

Member State	Marketing authorisation holder	Invented names	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
FINLAND	Solvay Pharmaceuticals BV C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands	Fevarin	50 mg 100 mg	Film coated tablets	Oral use	PVC/PVDC-A1 blisters	30, 60 and 90
FRANCE	Solvay Pharma 42, rue Rouget de Lisle BP 22 F-92151 Suresnes	Floxyfral	50 mg 100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC/Alu blisters	20, 30 and 50 Hospital pack of 100
GERMANY	Solvay Arzneimittel GmbH Hans-Boeckler-Allee 20 D-30173 Hannover	Fevarin	50 mg 100 mg	Film coated tablets	Oral use	PVC/PVDC blisters	20, 50 and 100 Hospital pack of 250 (5 × 50)
	Solvay Arzneimittel GmbH Hans-Boeckler-Allee 20 D-30173 Hannover	Fevarin Tabs	50 mg 100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC blisters	20, 50 and 100 Hospital pack of 250 (5 × 50)
GREECE	Solvay Pharma MEPE Ag. Dimitriou 63 GR-17456 Alimos	Dumyrox	50 mg 100 mg	Film coated tablets and enteric coated tablets	Oral use	PVC/PVDC blisters	30
	Famar ABE P. Marinopoulou 7 GR-174 56 Alimos	Luvox	50 mg 100 mg	Enteric coated tablets	Oral use	PVC/PVDC blisters	30
IRELAND	Solvay Healthcare Limited Mansbridge Road West End Southampton SO18 3JD United Kingdom	Faverin Tablets 50 mg and Faverin Tablets 100 mg	50 mg 100 mg	Coated tablets	Oral use	Blister strip	50 mg — 60 100 mg — 30
ITALY	Solvay Pharmaceuticals BV C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands	Fevarin	50 mg 100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC/alu opaque blisters	15 and 30
	Solvay Pharma SpA Via della Libertà 30 I-10095 Grugliasco (TO)	Dumirox	50 mg 100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC/alu opaque blisters	30
	Farmades SpA Via di Tor Cervara 282 I-00155 Roma	Maveral	50 mg 100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC/alu opaque blisters	30
LUXEMBOURG	Solvay Pharma & Cie., SNC-VOF Bd. Em. Bockstaellaan 122 B-1020 Brussels	Floxyfral	100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC blisters	20, 30 and 60 Hospital pack of 100 (UD)
	Solvay Pharma & Cie., SNC-VOF Bd. Em. Bockstaellaan 122 B-1020 Brussels	Dumirox	100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC blisters	30 and 60 Hospital pack of 100 (UD)
THE NETHERLANDS	Solvay Pharmaceuticals BV C.J. van Houtenlaan 36 1381 CP Weesp Nederland	Fevarin	50 mg 100 mg	Film coated, tablets	Oral use	PVC/PVDC-A1 blisters	50 mg — 30, 50 and 60 100 mg — 30 and 50

Member State	Marketing authorisation holder	Invented names	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
NORWAY	Solvay Pharmaceuticals BV C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands	Fevarin	50 mg 100 mg	Film coated tablets	Oral use	PVC/PVDC-A1 blisters	30 and 90
PORTUGAL	Solvay Farma Lda Av. Marechal Gomes da Costa, 33 P-1800-255 Lisboa	Dumyrox	50 mg 100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC/Alu blisters	50 mg — 20 and 60 100 mg — 30
SPAIN	Solvay Pharma SA Av. Diagonal, 507 E-08029 Barcelona	Dumirox 50 and Dumirox 100	50 mg 100 mg	Film coated, breakable tablets	Oral use	PVC/PVDC-A1 blisters	30
SWEDEN	Solvay Pharmaceuticals BV C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands	Fevarin	50 mg 100 mg	Film coated tablets	Oral use	PVC/PVDC-A1 blisters	30, 60 and 90
UNITED KINGDOM	Solvay Healthcare Limited Mansbridge Road West End Southampton SO18 3JD United Kingdom	Faverin Tablets 50 mg and Faverin Tablets 100 mg	50 mg 100 mg	Coated tablets	Oral use	Blister strip	50 mg — 60 100 mg — 30

ANNEX II

LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, STRENGTHS, PHARMACEUTICAL FORMS, ROUTE OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES

CISAPRIDE-CONTAINING MEDICINAL PRODUCTS WITH MARKETING AUTHORISATION IN THE EUROPEAN UNION

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
AUSTRIA	Janssen-Cilag Pharma GmbH Pfarrg. 75 A-1232 Wien	Prepulsid 1 mg/ml — orale suspension	1 mg/ml	Oral suspension	Oral use	Bottle	100 ml
	Janssen-Cilag Pharma GmbH Pfarrg. 75 A-1232 Wien	Prepulsid 1 mg/ml — orale suspension	1 mg/ml	Oral suspension	Oral use	Sachet	20 sachets of 5 ml 50 sachets of 5 ml 20 sachets of 10 ml 50 sachets of 10 ml
	Janssen-Cilag Pharma GmbH Pfarrg. 75 A-1232 Wien	Prepulsid 5 mg Tabletten	5 mg	Tablet	Oral use	Blister	10 20 30 50
	Janssen-Cilag Pharma GmbH Pfarrg. 75 A-1232 Wien	Prepulsid 10 mg Tabletten	10 mg	Tablet	Oral use	Blister	10 20 30 50

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
AUSTRIA (cont'd)	Janssen-Cilag Pharma GmbH Pfarrg. 75 A-1232 Wien	Prepulsid 20 mg Tabletten	20 mg	Tablet	Oral use	Blister	20
BELGIUM	Janssen-Cilag NV Roderveldlaan B-2600 Berchem	Prepulsid	5 mg	Tablet	Oral use	Strip	30 UD
	Janssen-Cilag NV Roderveldlaan B-2600 Berchem	Prepulsid	1 mg/ml	Oral suspension (adults)	Oral use	Bottle	100 ml
	Janssen-Cilag NV Roderveldlaan B-2600 Berchem	Prepulsid	1 mg/ml	Oral suspension	Oral use	Sachet	20 sachets of 5 ml
	Janssen-Cilag NV Roderveldlaan B-2600 Berchem	Prepulsid	10 mg	Tablet	Oral use	Strip	100
	Janssen-Cilag NV Roderveldlaan B-2600 Berchem	Prepulsid	20 mg	Tablet	Oral use	Strip	50 100 U.D.
	Janssen-Cilag NV Roderveldlaan B-2600 Berchem	Prepulsid	10 mg	Effervescent tablet	Oral use		20 100
	Janssen-Cilag NV Roderveldlaan B-2600 Berchem	Prepulsid	1 mg/ml	Oral suspension (paediatric)	Oral use	Bottle	100 ml
	Janssen-Cilag NV Roderveldlaan B-2600 Berchem	Prepulsid	1 mg/ml	Oral suspension	Oral use	Sachet	50 sachets of 10 ml
DENMARK	Janssen-Cilag A/S Postboks 149 Hammerbakken 19 DK-3460 Birkerød	Prepulsid	1 mg/ml	Oral solution	Oral use	Bottle (glass)	200 ml
	Janssen-Cilag A/S Postboks 149 Hammerbakken 19 DK-3460 Birkerød	Prepulsid	10 mg	Tablet	Oral use	Blister PVC-PE- PVDC/ALU	50 100
	Janssen-Cilag A/S Postboks 149 Hammerbakken 19 DK-3460 Birkerød	Prepulsid	20 mg	Tablet	Oral use	Blister PVC-PE- PVDC/ALU	50 100
	Janssen-Cilag A/S Postboks 149 Hammerbakken 19 DK-3460 Birkerød	Prepulsid	10 mg	Oral lyophilisate	Oral use	Blister PVC-PE/ALU	Not applicable since it is not marketed

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
DENMARK (cont'd)	Janssen-Cilag A/S Postboks 149 Hammerbakken 19 DK-3460 Birkerød	Prepulsid	20 mg	Oral lyophilisate	Oral use	Blister PVC-PE/ALU	Not applicable since it is not marketed
FINLAND	Janssen-Cilag Oy Metsänneidonkuja 8 FIN-02130 Espoo	Prepulsid	5 mg	Tablet	Oral use	Blister ALU/PVC/PVDC	30
	Janssen-Cilag Oy Metsänneidonkuja 8 FIN-02130 Espoo	Prepulsid	10 mg	Tablet	Oral use	Blister ALU/PVC/PVDC	50 100
	Janssen-Cilag Oy Metsänneidonkuja 8 FIN-02130 Espoo	Prepulsid	20 mg	Tablet	Oral use	Blister ALU/PVC/PVDC	60
	Janssen-Cilag Oy Metsänneidonkuja 8 FIN-02130 Espoo	Prepulsid	1 mg/ml	Oral suspension	Oral use	Bottle (glass)	100 ml 200 ml
	Janssen-Cilag Oy Metsänneidonkuja 8 FIN-02130 Espoo	Prepulsid	30 mg	Suppository	Rectal use	PVC/HDPE Blister	6
	Janssen-Cilag Oy Metsänneidonkuja 8 FIN-02130 Espoo	Prepulsid Quicklet	5 mg	Oral lyophilisate	Oral use	Blister aclar/alu	28 56
	Janssen-Cilag Oy Metsänneidonkuja 8 FIN-02130 Espoo	Prepulsid Quicklet	10 mg	Oral lyophilisate	Oral use	Blister aclar/alu	28 56
	Janssen-Cilag Oy Metsänneidonkuja 8 FIN-02130 Espoo	Prepulsid Quicklet	20 mg	Oral lyophilisate	Oral use	Blister aclar/alu	28 56
FRANCE	Janssen-Cilag 1, rue Camille-Desmoulins TSA 91003 F-92787 Issy les Moulineaux Cedex 9	Prepulsid 10 mg, comprimé	10 mg	Tablet	Oral use	PVC/PVDC/ Aluminium/ Polyethylene blister	40
	Janssen-Cilag 1, rue Camille-Desmoulins TSA 91003 F-92787 Issy les Moulineaux Cedex 9	Prepulsid adultes 1 mg/ml suspension buvable en flacon	1 mg/ml	Oral suspension	Oral use	Glass vial	200 ml
	Janssen-Cilag 1, rue Camille-Desmoulins TSA 91003 F-92787 Issy les Moulineaux Cedex 9	Prepulsid enfants et nourrissons 1 mg/ml suspension buvable en flacon	1 mg/ml	Oral suspension	Oral use	Glass vial	100 ml

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
FRANCE (cont'd)	Janssen-Cilag 1, rue Camille-Desmoulins TSA 91003 F-92787 Issy les Moulineaux Cedex 9	Prepulsid 5 mg/ 5 ml suspension buvable en sachet	5 mg/ 5 ml	Oral suspension	Oral use	Sachet paper/ alu/poly- ethelene/surlyn	20 40 Sachets of 5 ml
	Janssen-Cilag 1, rue Camille-Desmoulins TSA 91003 F-92787 Issy les Moulineaux Cedex 9	Prepulsid 10 mg/ 10 ml suspension buvable en sachet	10 mg/ 10 ml	Oral suspension	Oral use	Sachet paper/ alu/poly- ethelene/surlyn	20 40 Sachets of 10 ml
GERMANY	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Alimix	1 mg/ml	Oral suspension	Oral use	Bottle (amber glass)	100 ml, 200 ml, 5 × 100 ml (hospital pack), 5 × 200 ml (hospital pack), 100 ml (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Alimix 5 mg, Tabletten	5 mg	Tablet	Oral use	PVC-PE-PVDC/ Alu blister Alu/Alu blister	100 20 50 200 (10 × 20) (hospital pack) 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Alimix 10 mg, Tabletten	10 mg	Tablet	Oral use	PVC-PE-PVDC/ Alu blister Alu/Alu blister	100 20 50 200 (10 × 20) (hospital pack) 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Alimix 5 mg, Tabletten	20 mg	Tablet	Oral use	PVC-PE-PVDC/ Alu blister Alu/Alu blister	100 20 50 200 (10 × 20) (hospital pack) 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Cisaprid-Janssen 5 mg, Tabletten	5 mg	Tablet	Oral use	PVC-PE-PVDC/ Alu blister Alu/Alu blister	100 20 50 200 (10 × 20) (hospital pack) 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin	1 mg/ml	Oral suspension	Oral use	Bottle (amber glass)	100 ml, 200 ml, 5 × 100 ml (hospital pack), 5 × 200 ml (hospital pack), 100 ml (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin 5 mg, Tabletten	5 mg	Tablet	Oral use	PVC-PE-PVDC/ Alu blister Alu/Alu blister	100 20 50 200 (10 × 20) (hospital pack) 20 (sample pack not for sale)

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
GERMANY (cont'd)	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin 10 mg, Tabletten	10 mg	Tablet	Oral use	PVC-PE-PVDC/ Alu blister Alu/Alu blister	100 20 50 200 (10 × 20) (hospital pack) 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin 20 mg, Tabletten	20 mg	Tablet	Oral use	PVC-PE-PVDC/ Alu blister Alu/Alu blister	100 20 50 200 (10 × 20) (hospital pack) 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin Beutel 5 ml	5 mg/ 5 ml	Oral suspension	Oral use		20 × 5 ml, 50 × 5 ml, 20 × 5 ml (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin Beutel 10 ml	10 mg/ 10 ml	Oral suspension	Oral use		20 × 10 ml, 50 × 10 ml, 20 × 10 ml (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin lingual, 5 mg, Lutschtabletten	5 mg	Lozenge	Oral use	Aclar/Alu blister Alu/Alu blister	20 48 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin lingual, 10 mg, Lutschtabletten	10 mg	Lozenge	Oral use	Aclar/Alu blister Alu/Alu blister	20 48 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin lingual, 20 mg, Lutschtabletten	20 mg	Lozenge	Oral use	Aclar/Alu blister Alu/Alu blister	20 48 20 (sample pack not for sale)
	Janssen-Cilag Raiffeisenstraße 8 D-41470 Neuss	Propulsin Lösungstabletten 10 mg	10 mg	Effervescent tablet	Oral use		20
GREECE	Cosmopharm Ltd PO Box 42 GR-20100 Korinthos	Evifix	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Help Ltd 14 Valaoritou Street GR-14452 Metamorhosi — Athens	Lirebin	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Help Ltd 14 Valaoritou Street GR-14452 Metamorhosi — Athens	Lirebin	5 mg	Tablet	Oral use	Blister	30 500 (10 × 50)

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
GREECE (cont'd)	Help Ltd 14 Valaoritou Street GR-14452 Metamorhosi — Athens	Lirebin	10 mg	Tablet	Oral use	Blister	50 (2 × 25)
	Biomedica — Chemica SA 25 G. Lyra Street GR-14564 Kiphisia	Systilan	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Biomedica — Chemica SA 25 G. Lyra Street GR-14564 Kiphisia	Systilan	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Biomedica — Chemica SA 25 G. Lyra Street GR-14564 Kiphisia	Circocric	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Biomedica — Chemica SA 25 G. Lyra Street GR-14564 Kiphisia	Circocric	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Uni-Pharma 14th Km Athens-Lamia GR-14564 Kifisia — Athens	Oferin	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	200 ml
	Uni-Pharma 14th Km Athens-Lamia GR-14564 Kifisia — Athens	Oferin	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Chrispa 16th Km Marathona GR-15344 Palini — Athens	Bozaxtral	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Janssen-Cilag 56 Irinis Ave. GR-15121 Perxi — Athens	Alimix	5 mg	Tablet	Oral use	Blister	30
	Janssen-Cilag 56 Irinis Ave. GR-15121 Perxi — Athens	Alimix	10 mg	Tablet	Oral use	Blister	50 (2 × 25)
	Janssen-Cilag 56 Irinis Ave. GR-15121 Perxi — Athens	Alimix	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Janssen-Cilag 56 Irinis Ave. GR-15121 Perxi — Athens	Alimix	5 mg/ 5 ml	Oral suspension	Oral use	Sachet	20 sachets of 5 ml 50 sachets of 5 ml 20 sachets of 10 ml 50 sachets of 10 ml
Janssen-Cilag 56 Irinis Ave. GR-15121 Perxi — Athens	Alimix	30 mg	Suppository	Rectal use	Blister	6	

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
GREECE (cont'd)	Janssen-Cilag 56 Irinis Ave. GR-15121 Perxi — Athens	Alimix	20 mg	Tablet	Oral use	Blister	60 (3 × 20)
	Janssen-Cilag 56 Irinis Ave. GR-15121 Perxi — Athens	Alimix	10 mg	Tablet	Oral use	Blister	20 56
	Rafarm AEBE Kapodistriov and 12 Kopinthou Street GR-15451 N. Psychiko — Athens	Ruvetine	10 mg	Tablet	Oral use	Blister	50 (2 × 25)
	Rafarm AEBE Kapodistriov and 12 Kopinthou Street GR-15451 N. Psychiko — Athens	Ruvetine	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Rafarm AEBE Kapodistriov and 12 Kopinthou Street GR-15451 N. Psychiko — Athens	Ruvetine	20 mg	Tablet	Oral use	Blister	60 (3 × 20)
	Genepharm SA 18th Km Athens Marathona Ave. GR-15344 Palini — Attikis	Dolyzinax	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	150 ml
	Genepharm SA 18th Km Athens Marathona Ave. GR-15344 Palini — Attikis	Dolyzinax	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	BROS Ltd Galini and 15 Argis Street GR-15464 N. Kiphisia	Lamafer	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	BROS Ltd Galini and 15 Argis Street GR-15464 N. Kiphisia	Lamafer	5 mg	Tablet	Oral use	Blister	30 (3 × 10)
	BROS Ltd Galini and 15 Argis Street GR-15464 N. Kiphisia	Lamafer	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Kleva Ltd 189 Parnithos Ave. GR-13671 Acharnai — Attiki	Kinussen	5 mg	Tablet	Oral use	Blister	30 (3 × 10)
Kleva Ltd 189 Parnithos Ave. GR-13671 Acharnai — Attiki	Kinussen	10 mg	Tablet	Oral use	Blister	50 (5 × 10)	

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
GREECE (cont'd)	Kleva Ltd 189 Parnithos Ave. GR-13671 Acharnai — Attiki	Kinussen	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	200 ml
	Kleva Ltd 189 Parnithos Ave. GR-13671 Acharnai — Attiki	Kinussen	20 mg	Tablet	Oral use	Blister	60 (3 × 20)
	Faran ABEE Achaïas and Trizinias GR-14564 N. Kiphisia — Athens	Cefanyl	5 mg	Tablet	Oral use	Blister	30 (3 × 10)
	Faran ABEE Achaïas and Trizinias GR-14564 N. Kiphisia — Athens	Cefanyl	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Faran ABEE Achaïas and Trizinias GR-14564 N. Kiphisia — Athens	Cefanyl	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	200 ml
	Farmaten Ltd 68 Menaorou Street GR-10432 Athens	Nastilox	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Farmaten Ltd 68 Menaorou Street GR-10432 Athens	Nastilox	5 mg	Tablet	Oral use	Blister Bottle	30 (3 × 10) 250 500 1 000
	Farmaten Ltd 68 Menaorou Street GR-10432 Athens	Nastilox	10 mg	Tablet	Oral use	Blister Bottle	50 (5 × 10) 250 500 1 000
	Finifarm Ltd 5 Anavritis Street GR-11143 Athens	Spabucol	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Finifarm Ltd 5 Anavritis Street GR-11143 Athens	Spabucol	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	200 ml
	Anfarm Hellas SA 442 Acharnon Street GR-11143 Athens	Minsk	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Anfarm Hellas SA 442 Acharnon Street GR-11143 Athens	Minsk	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	200 ml
	Elpen SA Pharmaceutical Industry 21st Km Marathona Ave. GR-19009 Pikermi — Attiki	Elpegon	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
GREECE (cont'd)	Elpen SA Pharmaceutical Industry 21st Km Marathona Ave. GR-19009 Pikermi — Attiki	Elpegon	5 mg	Tablet	Oral use	Blister	30 (3 × 10)
	Elpen SA Pharmaceutical Industry 21st Km Marathona Ave. GR-19009 Pikermi — Attiki	Elpegon	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Remedina ABEE 25 Gounari GR-13451 Kamatero — Attiki	Zenopar	5 mg	Tablet	Oral use	Blister	30 (3 × 10)
	Remedina ABEE 25 Gounari GR-13451 Kamatero — Attiki	Zenopar	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Remedina ABEE 25 Gounari GR-13451 Kamatero — Attiki	Zenopar	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Antor Ltd 4 Omirou GR-15126 Marousi	Cevilor	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Zikides NG 45 Victoros Ougo GR-10437 Athens	Epasan	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	200 ml
	Zikides NG 45 Victoros Ougo GR-10437 Athens	Epasan	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Hexal Hellas 189 Parnithos Ave. GR-13671 Athens	Cisapride/Hexal	5 mg	Tablet	Oral use	Blister	30 (3 × 10)
	Hexal Hellas 189 Parnithos Ave. GR-13671 Athens	Cisapride/Hexal	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Hexal Hellas 189 Parnithos Ave. GR-13671 Athens	Cisapride/Hexal	5 mg/ 5 ml	Oral suspension	Oral use	Bottle	200 ml
	Medichrom SA 26th Km Markopoulou Ave. GR-19003 Koropi — Attiki	Gastridol	1 mg/ 1 ml	Oral suspension	Oral use	Bottle	200 ml

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
GREECE (cont'd)	Medichrom SA 26th Km Markopoulou Ave. GR-19003 Koropi — Attiki	Gastridol	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
	Komep SA Pireos and 64 Aristovoulou Street GR-11853 Athens	Saprimix	1 mg/ 1 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Komep SA Pireos and 64 Aristovoulou Street GR-11853 Athens	Saprimix	10 mg	Tablet	Oral use	Blister	50 (5 × 10)
IRELAND	Janssen-Cilag Ltd Saunderton High Wycombe Buckinghamshire HP14 4HJ United Kingdom	Prepulsid Suspension	1 mg/ml	Oral suspension	Oral use	Amber glass Bottle	200 ml 500 ml
	Janssen-Cilag Ltd Saunderton High Wycombe Buckinghamshire HP14 4HJ United Kingdom	Prepulsid Paediatric Suspension	1 mg/ml	Oral suspension	Oral use	Amber glass Bottle	100 ml
	Janssen-Cilag Ltd Saunderton High Wycombe Buckinghamshire HP14 4HJ United Kingdom	Prepulsid Tablets 5 mg	5 mg	Tablet	Oral use	ALU/PVC/PE/PVDC blister	6 10 60 84
	Janssen-Cilag Ltd Saunderton High Wycombe Buckinghamshire HP14 4HJ United Kingdom	Prepulsid Tablets 10 mg	10 mg	Tablet	Oral use	ALU/PVC/PE/PVDC blister	10 30 60 84 90 100 112 120
ITALY	J. C. Healthcare SRL Via Michelangelo Buonarroti, 23 I-20093 Cologno Monzese MI	Alimix	5 mg/ 5 ml	Oral suspension	Oral use	Sachet	30 sachets of 5 ml
	J. C. Healthcare SRL Via Michelangelo Buonarroti, 23 I-20093 Cologno Monzese MI	Alimix	10 mg/ 10 ml	Oral suspension	Oral use	Sachet	30 sachets of 10 ml
	Italchimici SpA Via G. Winckelmann, 2 I-20146 Milano (MI)	Cipril	10 mg	Tablet	Oral use	Blister	30

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
ITALY (cont'd)	Italchimici SpA Via G. Winckelmann, 2 I-20146 Milano (MI)	Cipril	1 mg/ 1 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Italchimici SpA Via G. Winckelmann, 2 I-20146 Milano (MI)	Cipril	10 mg	Effervescent granules	Oral use	Sachet	30
	Italchimici SpA Via G. Winckelmann, 2 I-20146 Milano (MI)	Cipril	5 mg	Chewable tablet	Oral use		28
	Italchimici SpA Via G. Winckelmann, 2 I-20146 Milano (MI)	Cipril	10 mg	Chewable tablet	Oral use		28
	Italchimici SpA Via G. Winckelmann, 2 I-20146 Milano (MI)	Cipril	5 mg/ 5 ml	Oral suspension	Oral use	Sachet	30 sachets of 5 ml
	Janssen Cilag SpA Via Michelangelo Buonarroti, 23 I-20093 Cologno Monzese MI	Prepulsid	1 mg/ 1 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Janssen Cilag SpA Via Michelangelo Buonarroti, 23 I-20093 Cologno Monzese MI	Prepulsid	10 mg	Effervescent granules	Oral use	Sachet	30
	Janssen Cilag SpA Via Michelangelo Buonarroti, 23 I-20093 Cologno Monzese MI	Prepulsid	5 mg	Chewable tablet	Oral use	Blister	28
	Janssen Cilag SpA Via Michelangelo Buonarroti, 23 I-20093 Cologno Monzese MI	Prepulsid	10 mg	Chewable tablet	Oral use	Blister	28
	Janssen Cilag SpA Via Michelangelo Buonarroti, 23 I-20093 Cologno Monzese MI	Prepulsid	5 mg/ 5 ml	Oral suspension	Oral use	Sachet	30 sachets of 5 ml
	Janssen Cilag SpA Via Michelangelo Buonarroti, 23 I-20093 Cologno Monzese MI	Prepulsid	10 mg/ 10 ml	Oral suspension	Oral use	Sachet	30 sachets of 10 ml
LUXEMBOURG	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Cyprid	5 mg	Tablet	Oral use	Strip	20 30

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
LUXEMBOURG (cont'd)	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Cyprid	1 mg/ml	Oral solution	Oral use	Bottle	100 ml
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Cyprid	5 mg/ 5 ml	Oral solution	Oral use	Sachet	20 sachets of 5 ml
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Cyprid	5 mg	Tablet	Oral use	Blister	20
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Prepulsid	10 mg	Tablet	Oral use	Strip	40 100
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Prepulsid	20 mg	Tablet	Oral use	Strip	50 100
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Prepulsid	1 mg/ml	Oral solution	Oral use	Bottle	100 ml
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Prepulsid	30 mg	Suppository	Rectal use	Strip	6
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Prepulsid	10 mg	Effervescent tablet	Oral use		20 100
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Prepulsid	10 mg/ 10 ml	Oral solution	Oral use	Sachet	50 sachets of 10 ml
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Prepulsid Quicklet	10 mg	Tablet	Oral use	Blister	20 56 100
	Janssen-Cilag NV Uitbreidingstraat 2 B-2600 Berchem	Prepulsid Quicklet	20 mg	Tablet	Oral use	Blister	20 56 100
THE NETHERLANDS	Janssen-Cilag BV Dr. Paul Janssenweg 150 5026 RH Tilburg Nederland	Prepulsid suspensie voor oraal gebruik 1 mg/ml	1 mg/ml	Oral suspension	Oral use	Bottle	
	Janssen-Cilag BV Dr. Paul Janssenweg 150 5026 RH Tilburg Nederland	Prepulsid Tabletten 5 mg	5 mg	Tablet	Oral use	Strip	
	Janssen-Cilag BV Dr. Paul Janssenweg 150 5026 RH Tilburg Nederland	Prepulsid Tabletten 10 mg	10 mg	Tablet	Oral use	Strip	

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
THE NETHERLANDS (cont'd)	Janssen-Cilag BV Dr. Paul Janssenweg 150 5026 RH Tilburg Nederland	Prepulsid Tabletten 20 mg	20 mg	Tablet	Oral use	Strip	
	Janssen-Cilag BV Dr. Paul Janssenweg 150 5026 RH Tilburg Nederland	Prepulsid Zetpillen 30 mg	30 mg	Suppository	Rectal use	Strip	
PORTUGAL	Laboratório B A Farma, Lda Rua Prof. Sousa da Câmara, n.º 207 a 211 Apartado 15087 P-1074-803 Lisboa	Ciside	10 mg	Tablet	Oral use	PVC/aluminium Blister	10 60
	Laboratório B A Farma, Lda Rua Prof. Sousa da Câmara, n.º 207 a 211 Apartado 15087 P-1074-803 Lisboa	Ciside	1 mg/ml	Oral suspension	Oral use	Amber-coloured glass bottle	200 ml
	Laboratório Azevedos — Indústria Farmacêutica, SA Estrada Nacional 117 2 Alfragide P-2724-503 Amadora	Clotioride	5 mg	Tablet	Oral use	PVC/aluminium blister	10 60
	Laboratório Azevedos — Indústria Farmacêutica, SA Estrada Nacional 117 2 Alfragide P-2724-503 Amadora	Clotioride	10 mg	Tablet	Oral use	PVC/aluminium blister	60
	Laboratório Azevedos — Indústria Farmacêutica, SA Estrada Nacional 117 2 Alfragide P-2724-503 Amadora	Clotioride	30 mg	Suppository	Rectal use	PVC polyethylene alveole	10
	Laboratório Azevedos — Indústria Farmacêutica, SA Estrada Nacional 117 2 Alfragide P-2724-503 Amadora	Clotioride	1 mg/ml	Oral suspension	Oral use	Amber-coloured glass bottle, PVC/alum. cap	200 ml
	Labesfal — Laboratórios Almiro, SA Campo de Besteiros Apartado 7 P-3465-051 Tondela	Hagascal	10 mg	Tablet	Oral use	PVC/aluminium blister	60
	Labesfal — Laboratórios Almiro, SA Campo de Besteiros Apartado 7 P-3465-051 Tondela	Hagascal	1 mg/ml	Oral suspension	Oral use	Amber-coloured glass bottle	200 ml

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
PORTUGAL (cont'd)	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	5 mg	Tablet	Oral use	PVC/PVDC/ PE/Aluminium blister	10 20 60
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	10 mg	Tablet	Oral use	PVC/PVDC/ PE/Aluminium blister	10 60
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	10 mg	Effervescent tablet	Oral use	Sachet Aluminium/ Aluminium	20 56
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	10 mg	Effervescent granules	Oral use	Polyethylene, aluminium and paper sachet	20
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	20 mg	Tablet	Oral use	PVC/PVDC/ PE/Aluminium blister	60
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	30 mg	Suppository	Rectal use	PVC and polyethylene	6
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	1 mg/ml	Oral suspension	Oral use	Amber-coloured glass bottles	100 ml 200 ml
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	5 mg/ 5 ml	Oral suspension	Oral use	Polyethylene/ aluminium/ paper/ionomer sachet	20 and 50 sachets of 5 ml
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid	10 mg/ 10 ml	Oral suspension	Oral use	Polyethylene/ aluminium/ paper/ionomer sachet	20 and 50 sachets of 10 ml

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
PORTUGAL (cont'd)	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid Quicklet	5 mg	Dispersible tablet	Oral use	Blister Aclar/ Aluminium	16 28 56
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid Quicklet	10 mg	Dispersible tablet	Oral use	Blister Aclar/ Aluminium	16 28 56
	Janssen Farmacêutica Portugal, Lda Estrada Consiglieri Pedroso, 69-a, Queluz de Baixo P-2749-503 Barcarena	Prepulsid Quicklet	20 mg	Dispersible tablet	Oral use	Blister Aclar/ Aluminium	16 28 56
SPAIN	Lab. Dr. Esteve SA Avda. Mare de Deu de Montserrat, 221 E-0841 Barcelona	Arcasín	10 mg	Tablet	Oral use	Blister	50
	Lab. Dr. Esteve SA Avda. Mare de Deu de Montserrat, 221 E-0841 Barcelona	Arcasín	10 mg/ 10 ml	Oral suspension	Oral use	Sachet (paper)	50
	Lab. Dr. Esteve SA Avda. Mare de Deu de Montserrat, 221 E-0841 Barcelona	Arcasín	20 mg	Tablet	Oral use	Blister	30
	Lab. Dr. Esteve SA Avda. Mare de Deu de Montserrat, 221 E-0841 Barcelona	Arcasín	1 mg/ 1 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml
	Lab. Dr. Esteve SA Avda. Mare de Deu de Montserrat, 221 E-0841 Barcelona	Arcasín	5 mg	Tablet	Oral use	Blister	30 60
	SALVAT, SA Gall, 30-36 E-08950 Esplugues de Llobregat (Barcelona)	Fisiogastrol	10 mg	Tablet	Oral use	PVC/AL blister	50 500
	SALVAT, SA Gall, 30-36 E-08950 Esplugues de Llobregat (Barcelona)	Fisiogastrol	10 mg/ 10 ml	Oral suspension	Oral use	Sachet	50 500
	SALVAT, SA Gall, 30-36 E-08950 Esplugues de Llobregat (Barcelona)	Fisiogastrol	1 mg/ 1 ml	Oral suspension	Oral use	Bottle	100 ml 200 ml

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
SPAIN (cont'd)	SALVAT, SA Gall, 30-36 E-08950 Esplugues de Llobregat (Barcelona)	Fisiogastrol	5 mg	Tablet	Oral use	PVC/AL blister	30 60 500
	Quimifar, SA Comandran, 37 E-08210 Barcelona	Kelosal	10 mg	Tablet	Oral use	PVC/PVDC/AL blister	50
	Quimifar, SA Comandran, 37 E-08210 Barcelona	Kelosal	5 mg	Tablet	Oral use	PVC/PVDC/AL blister	30 60
	Quimifar, SA Comandran, 37 E-08210 Barcelona	Kelosal	1 mg/ 1 ml	Oral suspension	Oral use	Bottle (glass)	100 ml 200 ml
	Janssen Cilag, SA Paseo de las doce estrellas, 5-7 E-28042 Madrid	Prepulsid	10 mg	Tablet	Oral use	Blister	50
	Janssen Cilag, SA Paseo de las doce estrellas, 5-7 E-28042 Madrid	Prepulsid	10 mg/ 10 ml	Oral suspension	Oral use	Sachet	50
	Janssen Cilag, SA Paseo de las doce estrellas, 5-7 E-28042 Madrid	Prepulsid	20 mg	Tablet	Oral use	Blister	30
	Janssen Cilag, SA Paseo de las doce estrellas, 5-7 E-28042 Madrid	Prepulsid	1 mg/ 1 ml	Oral suspension	Oral use	Bottle (plastic)	100 ml 200 ml
	Janssen Cilag, SA Paseo de las doce estrellas, 5-7 E-28042 Madrid	Prepulsid	5 mg	Tablet	Oral use	Blister	30 60
SWEDEN	Janssen Cilag AB Rotebergsvägen 1 Box 7073 S-19207 Sollentuna	Prepulsid	10 mg	Tablet	Oral use	PVC/ALU blister	50 100 250 100 (single dose package)
	Janssen Cilag AB Rotebergsvägen 1 Box 7073 S-19207 Sollentuna	Prepulsid	20 mg	Tablet	Oral use	PVC/ALU blister	100
	Janssen Cilag AB Rotebergsvägen 1 Box 7073 S-19207 Sollentuna	Prepulsid	1 mg/ml	Oral suspension	Oral use	Bottle (glass)	200 ml

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package sizes
UNITED KINGDOM	Janssen-Cilag Limited Saunderton High Wycombe Bucks HP14 4HJ United Kingdom	Prepulsid Tablets	5 mg	Tablet	Oral use	ALU/PE/PVC/ PVDC blister	6 10 60 84
	Janssen-Cilag Limited Saunderton High Wycombe Bucks HP14 4HJ United Kingdom	Prepulsid Tablets	10 mg	Tablet	Oral use	ALU/PE/PVC/ PVDC blister	10 30 60 84 90 100 112 120
	Janssen-Cilag Limited Saunderton High Wycombe Bucks HP14 4HJ United Kingdom	Prepulsid Suspension 1 mg/ml	1 mg/ml	Oral suspension	Oral use	Bottle (glass)	200 ml 500 ml
	Janssen-Cilag Limited Saunderton High Wycombe Bucks HP14 4HJ United Kingdom	Prepulsid Quicklet Tablets	5 mg	Quicklet tablet	Oral use	ALU/aclar foil blister	8 16 28 56 120
	Janssen-Cilag Limited Saunderton High Wycombe Bucks HP14 4HJ United Kingdom	Prepulsid Quicklet Tablets	10 mg	Quicklet tablet	Oral use	ALU/aclar foil blister	8 16 28 56 120
	Janssen-Cilag Limited Saunderton High Wycombe Bucks HP14 4HJ United Kingdom	Prepulsid Quicklet Tablets	20 mg	Quicklet tablet	Oral use	ALU/aclar foil blister	8 16 28 56 120

Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty

Cases where the Commission raises no objections

(2002/C 157/04)

Date of adoption of the decision: 29.6.2002

Member State: Finland

Aid No: N 94/02

Title: Aid for advertising horticultural products

Objective: The objective of the advertising campaigns is to increase the consumption of fruit and vegetables in Finland. The Finnish authorities have explained that the undertakings active in the horticultural sector in Finland are small and medium-sized enterprises (SMEs) and that the advertising campaigns promote the development of such enterprise.

Kotimaiset Kasvikset ry. (Finnish Horticultural Products Society, a Finnish registered association whose members include, for example, producer and wholesale organisations) intends to carry out several advertising campaigns, which promote the consumption and use of horticultural products, i.e. fruit and vegetables including flowers.

A maximum of 50 % of the costs of the advertising campaigns is to be financed with the proposed aid scheme. The remaining 50 % or more of the costs will be financed by the member organisations of Kotimaiset kasvikset ry. These member organisations receive the financing from their members, i.e. the producers

Legal basis: Decision of the Ministry of Agriculture and Forestry

Budget: Variable

Aid intensity or amount: Max. 50 % of the campaign costs, which have been estimated at EUR 1,17 million for 2002

Duration: The subsidised advertising campaigns would be carried out from 2002 to 2007

Other information: The draft measure would be carried out under an existing aid scheme, which has notified to the Commission on 24 April 1995 pursuant to Article 144 of the Act of Accession

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Objective: The aid programme envisages the maintenance of field and grassland areas which are valuable from a nature conservation point of view, through sustainable, extensive cultivation as well as the restoration of certain landscape elements

Legal basis: Richtlinie zur Förderung aus Mitteln des Landschaftspflegefonds

Budget: Approximately EUR 290 691 per year

Aid intensity or amount: Variable

Duration: Five years

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 29.6.2002

Member State: Spain (Catalonia)

Aid No: N 324/01

Title: Measures to integrate, set up and extend cooperatives

Objective: To promote the modernisation and integration of producer groups so as to help improve their economic and social direction by adopting management and marketing measures

Legal basis: Ley 50/85 de 27 de diciembre de incentivos regionales para la corrección de desequilibrios económicos interterritoriales. Real Decreto 1535/87, de 11 de diciembre, por el que se aprueba el reglamento de desarrollo de dicha Ley 50/85. Real Decreto 570/1988, de 3 de junio, de delimitación de la zona de promoción económica de Castilla y León

Budget: EUR 21 799 721

Aid intensity or amount: Varies according to the type of aid

Duration: Six years (2001-2006)

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 29.6.2002

Member State: Austria (Burgenland)

Aid No: N 310/01

Title: Cultural landscape programme

Date of adoption of the decision: 30.5.2002

Member State: Italy (Veneto)

Aid No: N 412/01

Title: Protection and improvement plan for the waters of the Venice basin — Intervention in the farming sector

Objective: Investments/agro-environmental commitments in regional protected areas

Legal basis: Piano per la prevenzione dell'inquinamento e il risanamento delle acque del bacino idrografico immediatamente sversanti nella Laguna di Venezia

Budget: Total budget EUR 30 987 413,93

Aid intensity or amount: Depending on the measure

Duration: Undetermined

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 29.6.2002

Member State: Spain

Aid No: N 611/01

Title: Processing and marketing in the agricultural, forestry and food sectors

Objective: To implement technical assistance plans in the sectors of processing and marketing agricultural, forestry and food products

Legal basis: Proyecto de Orden por la que se establecen las bases reguladoras de las subvenciones para planes de asistencia técnica y de gestión en los sectores de transformación y comercialización de productos agrarios, silvícolas, de pesca, acuicultura y alimentación

Budget: Unspecified

Aid intensity or amount: 50 % of expenditure

Duration: One year

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty

Cases where the Commission raises no objections

(2002/C 157/05)

Date of adoption of the decision: 17.5.2002

Member State: United Kingdom (Wales and England)

Aid No: N 10/02

Title: Foot and mouth disease business recovery fund

Objective: Assist ancillary agricultural businesses indirectly affected by foot and mouth disease but are not eligible for schemes targeted at farmers

Legal basis: Regional Development Agencies Act 1998 Section 5 (England). Local Government Act 2000, Section 2(1) (Wales)

Budget: GBP 3,5 million

Aid intensity or amount: Aid to operators not involved in the production, processing and marketing of Annex I products: measure not constituting aid. Aid to operators involved in the production, processing and marketing of Annex I products: up to 100 %

Duration: Until 31 June 2002

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 17.5.2002

Member State: Italy (Sardegna)

Aid No: N 31/02

Title: Additional interventions to compensate the farmers for losses due to blue tongue

Objective: Aid for recovering the losses due to the blue tongue

Legal basis: Legge 12 dicembre 2001 n. 16 «Ulteriore sostegno a favore degli allevatori per fronteggiare l'epizoozia denominata Blue tongue»

Budget: EUR 43 898 838

Aid intensity or amount: As described in the decision

Duration: Indeterminate

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 17.5.2002

Member State: United Kingdom (Northern Ireland)

Aid No: N 126/02

Title: Northern Ireland scrapie plan — genotyping scheme

Objective: Long-term initiative aimed at the reduction and eventual eradication of scrapie from Northern Ireland sheep flock

Legal basis: Non-statutory initiative

Budget: 2002/03: GBP 2,75 million; 2003/04: GBP 3,5 million

Duration: Unlimited

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 17.5.2002

Member State: Spain (Cantabria)

Aid No: N 249/02

Title: Aid for beekeeping

Objective: To maintain beekeeping

Legal basis: Proyecto de orden por la que se establece una prima de polinización destinada a los titulares de explotaciones apícolas de Cantabria

Budget: EUR 60 000 per year

Aid intensity or amount: Varies according to the beneficiaries

Duration: Unspecified

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 17.5.2002

Member State: United Kingdom (Northern Ireland)

Aid No: N 318/01

Title: Aujeszky's disease vaccination scheme

Objective: Favour the eradication of Aujeszky's disease in Northern Ireland

Legal basis: Aujeszky's Disease Scheme Order (Northern Ireland) 1994

Budget: GBP 150 000

Aid intensity or amount: 100 %

Duration: Until April 2002

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 17.5.2002

Member State: United Kingdom (Northern Ireland)

Aid No: N 718/B/01

Title: Buying time assistance scheme

Objective: Rescuing small and medium-sized enterprises from insolvency

Legal basis: Industrial Development (Northern Ireland) Order 1982

Budget: GBP 2 million

Aid intensity or amount: Up to EUR 10 million to any one firm

Duration: Indefinite

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Prior notification of a concentration
(Case COMP/M.2890 — EDF/Seeboard)

(2002/C 157/06)

(Text with EEA relevance)

1. On 24 June 2002 the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 ⁽¹⁾, as last amended by Regulation (EC) No 1310/97 ⁽²⁾, by which the undertaking London Electricity Group plc (LEG, United Kingdom), belonging to the group Electricité de France (EDF Group, France), in turn owned and controlled by the French State, acquires, within the meaning of Article 3(1)(b) of the Regulation, control of the whole of Seeboard plc (Seeboard, United Kingdom) by way of purchase of shares through a newly created company.

2. The business activities of the undertakings concerned are:

- LEG: Generation, transmission, distribution and supply of electricity and gas in the United Kingdom,
- Seeboard: Generation, distribution and supply of electricity and gas in the United Kingdom.

3. On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EEC) No 4064/89. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference COMP/M.2890 — EDF/Seeboard, to:

European Commission,
Directorate-General for Competition,
Directorate B — Merger Task Force,
J-70,
B-1049 Brussels.

⁽¹⁾ OJ L 395, 30.12.1989, p. 1; corrigendum: OJ L 257, 21.9.1990, p. 13.

⁽²⁾ OJ L 180, 9.7.1997, p. 1; corrigendum: OJ L 40, 13.2.1998, p. 17.

Notice under Section 12(2) of the Telecommunications Act 1984
Proposed modifications to the licence of British Telecommunications plc (BT)

(2002/C 157/07)

(Text with EEA relevance)

Published in the Belfast, Edinburgh and London Gazette on Friday 31 May 2002.

The link to the notice on Oftel's website is:

http://www.oftel.gov.uk/ind_info/licensing/mods/2002/galvin31502.htm
